CN103269694A - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
CN103269694A
CN103269694A CN2011800597356A CN201180059735A CN103269694A CN 103269694 A CN103269694 A CN 103269694A CN 2011800597356 A CN2011800597356 A CN 2011800597356A CN 201180059735 A CN201180059735 A CN 201180059735A CN 103269694 A CN103269694 A CN 103269694A
Authority
CN
China
Prior art keywords
pharmaceutical composition
fluticasone
formoterol
indenes
ciclesonide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800597356A
Other languages
English (en)
Chinese (zh)
Inventor
吉纳·麦赫特拉
施里尼瓦斯·马杜卡尔·普拉恩达利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to CN201711377918.8A priority Critical patent/CN107998109A/zh
Publication of CN103269694A publication Critical patent/CN103269694A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2011800597356A 2010-10-12 2011-07-25 药物组合物 Pending CN103269694A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711377918.8A CN107998109A (zh) 2010-10-12 2011-07-25 药物组合物

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
IN2847MU2010 2010-10-12
IN2847/MUM/2010 2010-10-12
IN69MU2011 2011-01-10
IN69/MUM/2011 2011-01-10
IN106MU2011 2011-01-12
IN106/MUM/2011 2011-01-12
IN135MU2011 2011-01-14
IN135/MUM/2011 2011-01-14
IN143/MUM/2011 2011-01-17
IN143MU2011 2011-01-17
PCT/GB2011/001115 WO2012049444A1 (en) 2010-10-12 2011-07-25 Pharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711377918.8A Division CN107998109A (zh) 2010-10-12 2011-07-25 药物组合物

Publications (1)

Publication Number Publication Date
CN103269694A true CN103269694A (zh) 2013-08-28

Family

ID=44651863

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800597356A Pending CN103269694A (zh) 2010-10-12 2011-07-25 药物组合物
CN201711377918.8A Pending CN107998109A (zh) 2010-10-12 2011-07-25 药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201711377918.8A Pending CN107998109A (zh) 2010-10-12 2011-07-25 药物组合物

Country Status (12)

Country Link
US (1) US10179139B2 (enExample)
EP (1) EP2627325A1 (enExample)
JP (2) JP2013542940A (enExample)
KR (2) KR20180028563A (enExample)
CN (2) CN103269694A (enExample)
AU (1) AU2011315315B2 (enExample)
BR (1) BR112013008974A2 (enExample)
CA (1) CA2814445A1 (enExample)
MX (1) MX2013004137A (enExample)
NZ (1) NZ609358A (enExample)
RU (1) RU2642624C2 (enExample)
WO (1) WO2012049444A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103784420A (zh) * 2014-02-18 2014-05-14 青岛市城阳区人民医院 马来酸茚达特罗液体制剂及其制备方法
CN109789151A (zh) * 2016-09-19 2019-05-21 墨西哥氟石股份公司 药物组合物
WO2021068961A1 (zh) * 2019-10-11 2021-04-15 四川海思科制药有限公司 一种吸入溶液药物组合物及其制备方法
WO2021227868A1 (zh) * 2020-05-14 2021-11-18 王兆霖 药物组合物制剂

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130274232A1 (en) 2010-07-16 2013-10-17 Cipla Limited Pharmaceutical Compositions
WO2012049444A1 (en) 2010-10-12 2012-04-19 Cipla Limited Pharmaceutical composition
EP3174522A1 (en) 2014-07-29 2017-06-07 3M Innovative Properties Company Method of preparing a pharmaceutical composition
AU2015393953B2 (en) * 2015-05-01 2021-09-02 Board Of Regents, The University Of Texas System Multidrug brittle matrix compositions
ES2826562T3 (es) * 2015-05-18 2021-05-18 Glenmark Specialty Sa Solución para inhalación de tiotropio por nebulizador
GB2554090A (en) * 2016-09-19 2018-03-28 Mexichem Fluor Sa De Cv Pharmaceutical compound
WO2018051132A1 (en) * 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
TR201712424A2 (tr) * 2017-08-21 2019-03-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Kuru toz i̇nhalasyon bi̇leşi̇mleri̇
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
CN111417917A (zh) 2018-01-24 2020-07-14 索尼公司 信息处理装置与信息处理方法
EA202092976A1 (ru) * 2018-06-04 2021-03-16 Люпин Инк. Устойчивые фармацевтические композиции для дозированных ингаляторов под давлением
WO2020105012A1 (en) * 2018-11-22 2020-05-28 Glenmark Specialty S.A. Sterile compositions of indacaterol suitable for nebulization
US20200215051A1 (en) * 2019-01-03 2020-07-09 Glenmark Specialty S.A. Nebulization composition comprising tiotropium and indacaterol
CN110840864B (zh) * 2019-12-20 2022-02-22 广州健康元呼吸药物工程技术有限公司 一种β2受体激动剂吸入气雾剂及包含该吸入气雾剂的产品
CN116963715A (zh) * 2020-09-29 2023-10-27 艾罗克斯医疗有限责任公司 茚达特罗的液体配制品
KR20250119514A (ko) * 2022-11-03 2025-08-07 다나-파버 캔서 인스티튜트 인크. 포르모테롤 또는 이의 약제학적으로 허용되는 염을 사용하여 빈혈을 치료하는 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101321539A (zh) * 2005-12-21 2008-12-10 Meda制药有限及两合公司 用于治疗炎性疾病的抗胆碱能药、糖皮质激素、β2－激动剂、PDE4抑制剂和抗白细胞三烯药的组合

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
US5879715A (en) 1997-09-02 1999-03-09 Ceramem Corporation Process and system for production of inorganic nanoparticles
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0009591D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medical combinations
JP4287613B2 (ja) 2000-04-28 2009-07-01 田辺三菱製薬株式会社 マイクロスフェアの製法
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
DE60321311D1 (de) * 2002-02-04 2008-07-10 Glaxo Group Ltd Zubereitung zur inhalation enthaltend ein glucocorticoid und einen beta 2-adrenorezeptor agonisten
EP2322243A1 (en) 2002-08-29 2011-05-18 Cipla Ltd. Pharmaceutical products and compositions comprising formoterol, ciclesonide and tiotropium
WO2004028545A1 (en) 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
EP1572217B1 (en) * 2002-12-12 2008-08-20 Nycomed GmbH Combination medicament of r,r-formoterol and ciclesonide
US6962006B2 (en) 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
WO2004110460A1 (en) 2003-06-13 2004-12-23 Altana Pharma Ag Formoterol and ciclesonide combination
SE527190C2 (sv) 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
SE527200C2 (sv) 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
US20050258288A1 (en) 2003-11-26 2005-11-24 E. I. Du Pont De Nemours And Company High pressure media milling system and process of forming particles
US20060008498A1 (en) 2004-07-12 2006-01-12 Chen Tzer-Fen D Nano-particle production
DE102004056578A1 (de) 2004-11-23 2006-05-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum, Formoterol und ein Steroid
JPWO2006073154A1 (ja) 2005-01-07 2008-06-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物及びその製造方法
CA2603433A1 (en) 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
WO2008064357A2 (en) 2006-11-22 2008-05-29 University Of Florida Research Foundation, Inc. Nanoparticles for protection of cells from oxidative stress
WO2008102128A2 (en) 2007-02-19 2008-08-28 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
TWI405590B (zh) 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
JP5109515B2 (ja) 2007-07-17 2012-12-26 株式会社ジェイテクト 摺動式トリポード形等速ジョイント
EP2197444A1 (en) * 2007-09-12 2010-06-23 Glaxo Group Limited Novel combination of therapeutic agents
DE102007054885A1 (de) 2007-11-15 2009-05-20 Evonik Degussa Gmbh Verfahren zur Fraktionierung oxidischer Nanopartikel durch Querstrom-Membranfiltration
FR2929136B1 (fr) 2008-03-25 2011-11-11 Sprainnov Procede et tete de pulverisation, procede et tour associes pour fabriquer un produit pulverulent
AU2009272445B2 (en) * 2008-07-18 2012-11-22 Circassia Limited Process for improving crystallinity
CN101474191B (zh) * 2009-01-21 2011-03-23 李虎山 一种治疗哮喘和慢性阻塞性肺病的药物组合物
US8668901B2 (en) * 2009-02-04 2014-03-11 Activaero Gmbh Research & Development Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma
EP2221048A1 (en) * 2009-02-18 2010-08-25 Siegfried Generics International AG Pharmaceutical composition for inhalation
MA33294B1 (fr) 2009-04-24 2012-05-02 Iceutica Pty Ltd Procédé destiné à la production de poudres de nanoparticules et de microparticules à usage commercial
GB0918431D0 (en) 2009-10-21 2009-12-09 Prosonix Ltd Process for improving crystallinity
WO2012049444A1 (en) 2010-10-12 2012-04-19 Cipla Limited Pharmaceutical composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101321539A (zh) * 2005-12-21 2008-12-10 Meda制药有限及两合公司 用于治疗炎性疾病的抗胆碱能药、糖皮质激素、β2－激动剂、PDE4抑制剂和抗白细胞三烯药的组合

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103784420A (zh) * 2014-02-18 2014-05-14 青岛市城阳区人民医院 马来酸茚达特罗液体制剂及其制备方法
CN109789151A (zh) * 2016-09-19 2019-05-21 墨西哥氟石股份公司 药物组合物
WO2021068961A1 (zh) * 2019-10-11 2021-04-15 四川海思科制药有限公司 一种吸入溶液药物组合物及其制备方法
CN113853197A (zh) * 2019-10-11 2021-12-28 四川海思科制药有限公司 一种吸入溶液药物组合物及其制备方法
WO2021227868A1 (zh) * 2020-05-14 2021-11-18 王兆霖 药物组合物制剂

Also Published As

Publication number Publication date
AU2011315315A1 (en) 2013-05-09
RU2013119938A (ru) 2014-11-20
RU2642624C2 (ru) 2018-01-25
MX2013004137A (es) 2013-07-29
CN107998109A (zh) 2018-05-08
NZ609358A (en) 2015-04-24
JP2017039746A (ja) 2017-02-23
US10179139B2 (en) 2019-01-15
KR20180028563A (ko) 2018-03-16
CA2814445A1 (en) 2012-04-19
US20140147393A1 (en) 2014-05-29
AU2011315315B2 (en) 2016-08-18
KR20140025308A (ko) 2014-03-04
WO2012049444A1 (en) 2012-04-19
EP2627325A1 (en) 2013-08-21
JP2013542940A (ja) 2013-11-28
BR112013008974A2 (pt) 2023-12-19

Similar Documents

Publication Publication Date Title
CN103269694A (zh) 药物组合物
AU2011278096B2 (en) Pharmaceutical compositions comprising R (+) budesonide and one or more bronchodilators
US20170027908A1 (en) Pharmaceutical Composition
WO2014016548A2 (en) Pharmaceutical composition
AU2017276321A1 (en) Pharmaceutical composition comprising arformoterol and fluticasone furoate
WO2012010854A1 (en) Inhalation formulations comprising carmoterol in combination with a corticosteroid
WO2012093252A1 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: India Mumbai PA rehl Ganbotelaao GA when Paimage Peninsula business park building Pula

Applicant after: Cipla Ltd.

Address before: Mumbai

Applicant before: Cipla Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130828